Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter Google Plus

Latest in Hematology-Oncology

Reuters Health • The Doctor's Channel Daily Newscast

Rituximab Safe for Cutaneous B-cell Lymphoma but Relapse Common

NEW YORK (Reuters Health) – A small study indicates that most patients with cutaneous B-cell lymphoma who respond well to rituximab relapse after about two years. On the positive side, the researchers found that rituximab treatment is not associated...
Researchers announced that two people with HIV infections are now apparently virus free since they received bone-marrow transplants for lymphoma and ceased taking antiretrovirals, The New York Times reports. These two cases, both in Boston, mirror...
The U.S. Food and Drug Administration granted marketing approval for Baxter International‘s Rixubis medication, according to Reuters. Rixubis is a “genetically engineered protein … that represents the first new treatment for [hemophilia...